Skip to main content
Home

Top menu InfoLep

  • About InfoLep
  • News & Events
  • e-learning.infoNTD.org
Home

Main navigation InfoLep

  • Leprosy [5]
    • Global and Regional Leprosy Situation
    • WHO Global Leprosy Strategy
    • ILEP Strategy
    • World Leprosy Day
    • Leprosy journals
  • Key topics [7]
    • Leprosy and COVID-19
    • Diagnostic tests
    • Prevention of leprosy [2]
      • Interventions to reduce transmission: post-exposure prophylaxis (PEP) [3]
        • LPEP Programme
        • PEP++ project
        • PEP4LEP project
      • Interventions to reduce transmission: vaccines
    • Rehabilitation & prevention of disability [2]
      • Preventing leprosy-related disabilities in girls and boys
      • Self-care in leprosy
    • Leprosy Antibiotic Treatment
    • Stigma, discrimination & mental wellbeing [4]
      • World Leprosy Day 2022
      • Gender
      • Mental wellbeing
      • SARI Project
    • Bioarchaeology of leprosy
  • Toolkits [6]
    • Guides on Stigma and Mental Wellbeing [5]
      • Guide 1. What are health-related stigma and mental wellbeing? [8]
        • 1. What is stigma?
        • 2. Why does stigma exist?
        • 3. What are the causes of stigma?
        • 4. Who stigmatises?
        • 5. How does it feel to experience stigma?
        • 6. What are the effects of stigma?
        • 7. Effects of stigma and discrimination on mental wellbeing
        • Annex Guide 1
      • Guide 2. How to reduce the impact of stigma [7]
        • 1. From undetected disease to diagnosis to support
        • 2. Individual-level interventions
        • 3. Group-level interventions
        • 4. Family-level interventions
        • 5. Referral
        • 6. Further reading
        • Annexes Guide 2
      • Guide 3. How to reduce sources of stigma [6]
        • 1. Background to the design of a stigma-reduction intervention
        • 2. Identifying the sources of stigma
        • 3. Targeting an intervention
        • 4. Inclusion of affected persons and champions in interventions
        • 5. Interventions by source type
        • Annexes Guide 3
      • Guide 4. How to assess health-related stigma and mental wellbeing [9]
        • 1. What is the purpose of the assessment?
        • 2. What approach would best fit your purpose and context?
        • 3. Quantitative assessment methods
        • 4. Qualitative assessment methods
        • 5. Assessments using mixed methods
        • 6. Developing qualitative methods from scratch
        • 7. How do you conduct a stigma assessment?
        • 8. How to interpret and report your findings
        • Annexes Guide 4
      • Glossary
    • NTD Morbidity and Disability Toolkit [15]
      • CHIEF
      • Clinical Profile
      • EMIC affected persons
      • EMIC-CS Community Stigma
      • Participation Scale
      • Patient Health Questionnaire (PHQ-9)
      • 5-Question Stigma Indicators
      • Salsa Scale
      • SARI Stigma Scale
      • SDS Social Distance Scale
      • SRQ Self-reporting Questionnaire
      • Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)
      • WGQ Washington Group Questions
      • WHODAS
      • WHOQOL-BREF
    • Perception Study Toolkit (PST)
    • Zero Leprosy Toolkit
    • CBM's Community Mental Health Good Practice Guides
    • GPZL & Infolep Factsheets
  • Online courses

Top menu InfoLep

  • About InfoLep
  • News & Events
  • e-learning.infoNTD.org
Visit our e-learning platform
Search resources Search in Practical Materials, Publications, Organizations, Online Course and more
Publication

The growing threat of antimicrobial resistance in Mycobacterium leprae: A literature review

Lukito AA, Komang Brahma Paralaga IB, Komang Harry Supradnyan I. Intisari Sains Medis. 2024;
Download PDF
Publication

Leprosy and Lupus: Concurrence or Epiphenomenon

Parekh A, Shah H, Chavda A. Indian Journal of Leprosy. 2024;
Download PDF
Publication

Trend and Factors Associated with Medical-Surgical Complications in Patients Discharged from Leprosy Multidrug Therapy at the Specialized Regional Hospital in Macenta, Guinea, from 2012 to 2021.

Hébélamou J, Grovogui F, Manet H, et al. Tropical medicine and infectious disease. 2024; 9 (12) : 1-9.
Download PDF
Publication

An alternative multidrug regimen for multibacillary Hansen's disease: a case report.

Akhverdyan N, Cantor Z, Hawkins K. Journal of medical case reports. 2024; 18 (1) : 1-4.
Download PDF
Publication

Avaliação da eficácia da ampliação do uso de clofazimina no tratamento de hanseníase

Gonçalves SGR, Gonçalves SGR, Oliveira XMFLD, et al. Brazilian Journals. Cuadernos de Educación y Desarrollo. 2024; 16 (12 Edição Especial) : 1-12.
Download PDF
Publication

Clofazimine-induced crystalline keratopathy in a leprosy patient.

Agarwal R, Tripathi A, Parveen S, et al. BMJ case reports. 2024;
Publication

Exploring The Neurological Manifestations of Leprosy: Clinical Insights and Implications

Pitton Rissardo J, Byroju VV, Fornari Caprara AL. MDPI AG. 2024;
Download PDF
Publication

Severe Erythema Nodosum Leprosum in Lepromatous Leprosy Patient

Pramudita AW, Kariosentono H, Evanti AM, et al. PT Kalbe Farma Tbk.. Cermin Dunia Kedokteran. 2024; 51 (12) : 696-699.
Download PDF
Publication

Lucio’s phenomenon in a non-endemic region: A case report

Yu AC, Chan AR, Chow EY. SAGE Publications. SAGE Open Medical Case Reports. 2024;
Download PDF
Publication

Persistence of Bacteriological Index After 1 Year of Multidrug Therapy Intake in Hansen’s Patients: An Indication to Strengthen the Antimicrobial Surveillance

Samal A, Singh BSTP, Kar BR. Ovid Technologies (Wolters Kluwer Health). Indian Dermatology Online Journal. 2024;
Download PDF

Pagination

  • Previous page ‹‹
  • Page 2
  • Next page ››
Subscribe to Multi-drug therapy (MDT)

Quick links

  • Leprosy
  • Key topics
  • Toolbox
  • Publications

Support

  • Contact
  • Privacy statement
  • Contact
  • FAQ

Contact us

info@infolep.org

(+31) 20 595 0500

     

Stay up to date with the latest publications and news related to leprosy.

Subscribe to newsletter

Related websites:

  • infontd

© 2025 InfoNTD